News

Johnson & Johnson submitted its single-shot COVID-19 vaccine to U.S. regulators recently for emergency use authorization after the vaccine was shown to be effective against illness and preventing severe disease and death.

Dorit Rubinstein Reiss and Arthur L. Caplan contributed a recent editorial to Health Affairs discussing how healthcare workers with temporary, unpleasant side effect from COVID-19 vaccines deserve appropriate time off without having to use up their regular sick leave or paid time off.

The move to put Witty in charge of the healthcare giant is described as "abrupt."

She helped launch the ACA as a top Obama administration official.

Based on results of the VISION study, the FDA has granted accelerated approval to tepotinib for MET exon 14 skipping altered metastatic non–small cell lung cancer.

Greater investment in AI and data security are among the keys.

Costs for electronic processing have decreased as costs for manual and partially electronic transactions have increased, resulting in opportunities to save $16.3 billion in the future.

In this episode of Tuning In to the C-Suite, MHE Associate Editor Briana Contreras spoke with Associate Dean for Equity Inclusion and Research Professor in the College of Nursing at Penn State University, Dr. Sheldon Fields. He is also the first Vice President for the National Black Nurses Association. In celebration of Black History Month, the two discussed racial equity in healthcare and what is being done for patients and nurses of color toward the improvement of the racial and health disparities that take place in care.

The findings suggest patients with HIV should be recategorized to "increased risk" when looking at COVID-19 underlying medical conditions.

Managed care organizations must ensure that all of their members—including their youngest—receive the most equitable start in life. Here’s how to get started.

Sports have been impacted by the pandemic from professional leagues, to youth and school activities, and even sports medicine. According to Aaron Smith, CEO of orthopedic medtech company, Artelon, sports medicine has become less about bones and muscle, and more about epidemiology.

CVS Health will begin to offer COVID-19 vaccinations February 11 to eligible populations, specifically those in underserved populations, at a limited number of CVS Pharmacy locations across 11 states in the United States.

The pandemic has led to the adoption of telehealth and greater access to care through apps.

Aurinia’s Lupkynis, used in combination with a background immunosuppressive therapy regimen, is available now.

Biosimilars may reduce healthcare costs.

Generic drugs account for 90% of the prescriptions filled in the United States. They are the backbone of healthcare providers’ treatment protocol and they are remarkably cost effective: despite being 90% of the prescriptions filled, generics account for only 20% of drug spending.

Commercial health insurance plan enrollees are more likely to take glucose-lowering medications.

Potential ACA marketplace enrollees are younger and likely to be healthier on average

Johnson & Johnson and a Maryland biotech company announced phase 3 results. Other COVID-19 vaccine news: WHO changes its advice for pregnant women, unofficial websites for looking up where you can get vaccinated, a call to stop hospital board members and donors from jumping the queue.

In this second part of a two-part video series, MHE Senior Editor Peter Wehrwein and Associate Editor Briana Contreras speak with Perry Cohen, Pharm. D., CEO of The Pharmacy Group. Perry has been on MHE's Editorial Advisory Board for over 25 years and has contributed a number of interviews and guest articles toward the publication. In this discussion, Briana, Peter and Perry talked about Sweden, Japan and the United States' response to COVID-19 and Cohen addresses the U.S.'s response under the new President Joe Biden Administration.

MHE Associate Editor Briana Contreras and Senior Editor Peter Wehrwein speak with Julie Olson, senior director of Population Health and Product Development at Navitus, a full pass-through pharmacy benefits management (PBM) company. In this discussion they talked about how Navitus has created a Clinical Engagement Center designed to improve medication adherence and reduce both member and plan prescription costs, while easing benefit transitions. Additionally, they discussed what it means to be a “full pass-through” PBM and how it compares to other PBMs.

Everyone will have a different confidence level based on their experience with vaccines in the past, and their comfort level with their local hospital, pharmacy chain or pharmacy. But once we get to the point where there are enough vaccines, Dan Rodriguez, R.Ph, BS, Pharm, believes “this process will run like a flu clinic – I don't think there's going to be that level of distrust or unease.”

In this first of a two-part video series, MHE Senior Editor Peter Wehrwein and Associate Editor Briana Contreras speak with Perry Cohen, Pharm. D., CEO of The Pharmacy Group. Perry has been on MHE's Editorial Advisory Board for over 25 years and has contributed a number of interviews and guest articles toward the publication. In this discussion, Briana, Peter and Perry talked about the current pharmacy benefits market as well as Sweden, Japan and the United States' response to COVID-19.

The organizations give recommendations on how to get patients to receive the care they need.

Expanding public health insurance may help curb the HIV epidemic.

FDA approves first complete long-acting HIV-1 treatment

In this episode of Tuning In to the C-Suite's Meet the Board series, MHE Senior Editor Peter Wehrwein and Associate Editor Briana Contreras speak with Perry Cohen, Pharm. D., CEO of The Pharmacy Group. Perry has been on MHE's Editorial Advisory Board for over 25 years and has contributed a number of interviews and guest articles toward the publication. In this discussion, Briana, Peter and Perry talked about the current pharmacy benefits market as well as Sweden, Japan and the United States' response to COVID-19.

FDA cleared cabozantinib (Cabometyx) for patients with advanced renal cell carcinoma as a first-line treatment in combination with nivolumab (Opdivo).